Literature DB >> 26706491

A Systematic Review on Effect of Single-Dose Preoperative Antibiotics at Surgical Osteotomy Extraction of Lower Third Molars.

Karoline Brørup Marcussen1, Anne Sofie Laulund2, Henrik L Jørgensen3, Else Marie Pinholt4.   

Abstract

PURPOSE: We conducted a systematic review of randomized controlled trials (RCTs) to evaluate the effectiveness of a single dose of preoperative antibiotic administered perorally, intravenously, intramuscularly, or topically for preventing infection and alveolar osteitis in lower third molar surgical extraction applying osteotomy.
MATERIALS AND METHODS: The Medline, Cochrane Library, and Embase databases were searched for RCTs until August 2015. The primary outcome measure was postoperative inflammatory reactions, with a subgroup analysis of surgical site infection (SSI) and alveolar osteitis. A risk-of-bias assessment of the included trials was done according to the Cochrane guidelines.
RESULTS: A total of 53 RCTs were identified; however, only 10 could be included in the present review. A meta-analysis of the 10 trials showed a statistically significant reduction in SSI and alveolar osteitis when antibiotics had been used (odds ratio [OR] = 0.30; 95% confidence interval [CI], 0.19 to 0.47; P ≤ .00001). A subgroup meta-analysis of 6 trials showed that preoperative administration of antibiotics perorally or intravenously significantly reduced the incidence of SSI (OR = 0.19; 95% CI, 0.08 to 0.45; P = .0002). A meta-analysis of 5 trials showed that 2 g of preoperative oral amoxicillin was able to reduce the incidence of SSI and the difference was statistically significant (OR = 0.22; 95% CI, 0.08 to 0.59; P = .002). Seven trials reported on alveolar osteitis, 6 studies on oral use, 2 studies on amoxicillin, 2 on metronidazole, 2 on penicillin V, and 1 on the intravenous use of penicillin. The pooled results showed that preoperative antibiotics significantly reduced the prevalence of alveolar osteitis (OR = 0.35; 95% CI, 0.13 to 0.96; P = .04). The subgroup analysis showed that penicillin V was effective in reducing the incidence of alveolar osteitis (OR = 0.1; 95% CI, 0.03 to 0.30; P ≤ .0001).
CONCLUSIONS: A single oral dose of 2 g of amoxicillin before lower third molar osteotomy surgical extraction significantly decreased the incidence of SSI. A single dose of 0.8 g of penicillin V before lower third molar osteotomy surgical extraction significantly decreased the incidence of alveolar osteitis.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26706491     DOI: 10.1016/j.joms.2015.11.017

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  4 in total

1.  Necessity of Antibiotics to Reduce Inflammatory Complications after Third Molar Extractions: A Prospective Study.

Authors:  Mohammed Jafnan Al Harbi; Moayad Ahmed A Alomaym; Mohammed Fahad Mohammed Aldohan; Ibrahim Fahad Alkurdi
Journal:  J Pharm Bioallied Sci       Date:  2019-02

2.  Inhibitory effect of topical antibiotics/antiseptics administration on bacterial growth in the open wound of the jawbone surgery: Randomized controlled, preliminary study.

Authors:  Souichi Yanamoto; Sakiko Soutome; Shoma Tsuda; Kota Morishita; Saki Hayashida; Saori Harata; Maho Murata; Keisuke Omori; Satoshi Rokutanda; Masahiro Umeda
Journal:  J Dent Sci       Date:  2020-07-03       Impact factor: 2.080

Review 3.  Infection, Alveolar Osteitis, and Adverse Effects Using Metronidazole in Healthy Patients Undergoing Third Molar Surgery: A Meta-analysis.

Authors:  Mario Alberto Isiordia-Espinoza; Othoniel H Aragon-Martinez; Ronell E Bollogna-Molina; Ángel J Alonso-Castro
Journal:  J Maxillofac Oral Surg       Date:  2017-07-01

Review 4.  Angiogenesis and the prevention of alveolar osteitis: a review study.

Authors:  Mohammad Ali Saghiri; Armen Asatourian; Nader Sheibani
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2018-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.